Affiliation:
1. Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
2. Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Abstract
Multi-cancer early detection tests (MCEDs) are blood-based tests that detect biomarkers released or induced by cancer cells. If MCED tests are shown to be safe and effective in cancer screening, they are likely to be ordered and managed in primary care. To understand primary care providers’ support for and concerns about the implementation and management of MCED testing, the research team developed a cross-sectional survey that was sent to 939 primary care providers (physicians, residents/fellows, and advanced practice providers) in a large academic health system in the greater Philadelphia area. The survey included standard items used to assess provider background characteristics and to measure provider awareness of challenges related to MCED test use (7 items), perceived competence in MCED testing (5 items), and receptivity to MCED test use in the future (4 items). A total of 351 (37.4%) primary care providers completed the survey. Among respondents, the awareness of challenges in MCED testing (mean = 3.95, sd = 0.64), perceived competence (3.67, sd = 0.85), and receptivity to MCED use in practice (mean = 3.62, 0.75) were moderately high. Multiple regression was performed to identify factors associated with receptivity to MCED testing. We found that provider number of years in practice (DATA), awareness of challenges related to MCED testing (DATA), and perceived competence in MCED test use (DATA) were positively and significantly associated with receptivity to MCED test use in practice. An exploratory factor analysis extracted two components: receptivity to MCEDs and awareness of challenges. Surprisingly, these factors had a positive correlation (r = 0.124, p = 0.024). Providers’ perceived competence in using MCED tests and providers’ experience level were significantly associated with receptivity to MCED testing. While there was strong agreement with potential challenges to implementing MCEDs, PCPs were generally receptive to using MCEDs in cancer screening. Keeping PCPs updated on the evolving knowledge of MCEDs is likely critical to building receptivity to MCED testing.
Funder
Exact Sciences Corporation
Thomas Jefferson University’s Sidney Kimmel Cancer Center
Reference33 articles.
1. (2023, April 13). FastStats—Leading Causes of Death, Available online: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
2. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
3. (2023, April 13). Recommendation: Breast Cancer: Screening|United States Preventive Services Taskforce. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening.
4. US Preventive Services Task Force (2018). Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA, 320, 674–686.
5. US Preventive Services Task Force (2021). Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA, 325, 1965–1977.